Abstract: Rational design in protein engineering leads to significant progresses in medicinal chemistry research. It alleviates the difficulty of exploring unreasonable biological functions. Combining with analysis of biophysical-chemical properties, a three-dimensional (3D) structure provides fruitful information for rational design by revealing functionally important residues. Comparative (homology) modeling, one of the 3D structural prediction techniques, takes advantage of that homologous proteins share similarity in their 3D structures despite the lack of sequence similarity. Of the most value, 3D models provide functional clues even though the function may have been modified during evolution.
INTRODUCTION
Future advances in medicinal chemistry involve the search for new pharmaceuticals with ever increasing potency and decreasing side effects. Two perspectives on this issue are worth of an endeavor. First, design new drugs for existing targets or improve/tailor already existent drugs. Second, explore for new targets. Thanks to the recent progress in genomics, a huge quantity of potential targets is available. One challenge to pharmaceutical industries is identifying relevant physiological targets to open new avenues to therapeutic treatments.
The recent explosion of "omics" fields (e.g., proteomics, transcriptomics, genomics… ) has induced a radical change in the way of modern biomedical research that is conducted by which one starts at a gene instead of a biological function. Identifying the protein function from a deduced amino-acid sequence is challenging to bioinformatics. To attack this task, one stream of bioinformatics groups attempts to annotate the function of all gene expression products using evolutionary linkage (sequence-based). Alternatively, the other stream attempts to acquire knowledge of protein functions from analyzing their three-*Address correspondence to this author at the CEA Valrhô -Centre de Marcoule, DSV/DIEP/SBTN, BP17171, 30207 Bagnols sur Cèze Cedex, France; Tel: +33 (0) 466 79 1943 ; Fax: +33 (0) 466 79 1905 ; E-mail: jlpellequer@cea.fr dimensional (3D) structures. Research of the second stream is characterized as the so-called structural bioinformatics or molecular modeling [1] . It encompasses the determination and prediction of 3D structure, ligand-protein and proteinprotein docking, molecular dynamics, and ultimately, the functional evaluation of a 3D structure and proposing useful testable hypotheses. The advantage of investigating 3D structures relies on identification of surface-exposed residues or finding the binding interface that can immediately provide a logical framework for further experiments.
Beneficiary of a finite number of protein folds discovered annually compared to the large number of crystal structures determined, the comparative (homology) modeling technique becomes central to molecular modeling. Comparative modeling allows us to predict the 3D structure of a protein based on available structures of homologous proteins that share significant sequence similarity and found in databases [2] [3] [4] [5] [6] . Comparative models have been shown to play a critical role at predicting docking orientation between ligands and receptors, and at identifying putative regions interacting with other molecules. Binding of ligands to receptors is at the heart of medicinal chemistry and molecular modeling fields. Development of protein inhibitors was successful in several cases such as the dihydrofolate reductase [7, 8] , prealbumine [9] , carbonic anhydrase [10] , thymidilate synthase [11] [12] [13] , purine nucleoside phosphorylase [14] [15] [16] [17] [18] , thrombin [19] , HIV protease [20] , interleukin-2 [21] or the tyrosine kinase receptor erbB [22] . Molecular modeling techniques were also successful in predicting putative interaction sites, such as a basic peptide site in calmodulin [23] , ATP in a kinase [24] , a linear epitope in C4b protein [25] , heparin in a protease [26] , LH/CG hormone to its receptor [27] , prostaglandine H2 to its receptor [28] , DNA binding site in a synthase [29] , Arp and heparin on C4b [30] .
Two questions are raised regarding validation of comparative models. Does the accuracy of a model influence functional predictions? Can a model support a functionalrelevant hypothesis using a distantly-related protein as the structural template? Structural accuracy was primarily pursued for validating a comparative model by measuring the root-mean-square deviation of the global cartesian coordinates (RMSD) from the crystallographic ones [31, 32] . It showed that structurally conserved regions were reasonably well modeled while non-homologous regions were not. Conformational analysis on numerous modeled structures and their subsequently X-ray determined structures was undertaken [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . In 1994, John Moult and his colleagues initiated the critical assessment of techniques for protein structure prediction (CASP) experiments [49] which allowed a worldwide survey of comparative modeling algorithms for a bona fide blind prediction of protein structures [50] [51] [52] [53] . Despite enormous improvements in comparative modeling, marginal progress was made in evaluating the prediction of protein functions. In particular, detailed evaluations of comparative models built from a distantly-related template are rarely performed. For several years, we have been involved in multi-disciplinary projects in medicinal and environmental chemistry. We applied the comparative modeling technique to projects where models could play a crucial role in elucidating molecular mechanism. A tight collaboration among clinicians, molecular biologists, and molecular modelers has been shown a promising strategy for fostering continuous advances in biomedical research. The goal of this review is to illustrate two successful collaborations by stressing on expectations and limitations in molecular modeling. The first study reveals that in such a category of modeling where errors are anticipated, functional hypothesis derived from a model can still be accurately predicted. In the second study, in which the accuracy of the model was expected to be high, we show that functional hypothesis goes beyond simply the analysis of the coordinates of a model on which molecular docking can be obtained with a reasonable success. The two examples highlight that comparative modeling combined with structural analysis is indispensable in modern medicinal and environmental chemistry.
COMPUTATIONAL METHODOLOGY
Our comparative modeling technique consists of three procedures. First, select one or several template proteins of which the 3D structure is available in databases. Second, predict the side-chain conformation of substituted residues. The last, construct the atomic positions in the regions where insertions or deletions (indels) of residues are in need.
Although good sequence alignments remain the key to successfully comparative modeling, we concentrated on testing parameters used in our procedures for side-chain and loop modeling. To further identify conserved structural regions for building the framework of targets, we used the CLUSTALW [54] and T-COFFEE [55] programs to perform multiple sequence alignment on the selected templates. Subsequently, we used an in-house sequence-based structure superposition program with a rigid body superposition algorithm to examine the indels locations.
Positioning Side Chains of Residues
All atoms of identical residues in the template were kept and residues requiring side-chain replacement were clustered. A cluster is characterised as a group of substituted residues in which one member has a distance within a user-provided value between the positions of its Cβ and Cβ of at least one another member. More explicitly, a cluster contains residues A, B, and C, for example. B may be spatially close both to A and C, but A and C are not necessarily close to each other. Consequently, all residues in the same cluster are distant from any member in all other clusters. Side-chain replacement was carried out by a two-stage scheme of energy minimisation. Throughout our protocol, energy minimizers use the Powell algorithm [56] unless mentioned otherwise. To conquer the computational difficulty in the side-chain modeling due to the huge amount of degrees of freedom in the conformational space, we adopted a rotamer library based approach to the first stage of this procedure. We searched for the energetically optimal rotamer combination by optimising a set of integers, i.e., the rotamer of individual residues, at a cluster level. At the second stage, we optimised χ dihedral angles of side chains locally around the output of the rotamer minimizer at a residue level. The angle deviation range was set to from 120° to -120°. This step is to remedy the limited rotamer representation of side-chain conformations by tuning the atomic positions.
Loop Closure
We constructed the initial atomic positions of a loop by sequentially attaching residues to the edged residues at both sides of the indels region with an arbitrary set of coordinates of amino acids. To better close the loop, we built the backbone trace first by optimising φ,ψ dihedral angles one by one from the disconnected residues (where the peptide bond needs to be formed) to the edged residues with the Golden Rule minimizer [56] . The range of φ,ψ dihedral angles was set between 120° and -120° deviated from the initial value. This step attempts to remove severe clashes between the loop backbone atoms and the protein environment. The influence of side-chain conformation on the determination of the backbone trace was taken into account, however, the optimisation scheme of side-chain placement was only performed during rotamer optimization. If the resultant structure of the loop was qualified to energetic and geometric criteria, then the program called the exit. Otherwise, subsequently simultaneous optimisation of all φ,ψ dihedral angles would be carried out. The deviation range in backbone conformational space was uniformly set from -60° to 60° for all φ's and ψ's .
Scoring Function
We used non-bonded energy to evaluate the fitness of molecular structures. Other energy terms of intra-molecular interactions were handled by imposing geometric constraints on the molecule. The non-bonded energy was expressed as the sum of van der Waals and electrostatic interactions. Both potential energies were represented as the Lennard-Jones and Coulomb functions, respectively. The effect of hydrogen bonds was taken implicitly into account by appropriate parameterization of the partial charges and the Lennard-Jones coefficients. We employed the CHARMM-22 force field [57] parameters where the value of the dielectric constant used in the Coulomb potential function equals 8.0. A residue-based interaction cut-off distance was set to 8 Å, i.e., a pair of residues was considered in the mutual force field if any pair of their heavy atoms is within this distance. Additionally minor refinements were performed for the completed models using the energy minimization program of XPLOR [58] where the CHARMM-22 force field was also employed. To avoid over-minimization, the convergence criterion was set between 1 and 4 Kcal/mole/ Å. The Coulomb interaction was turned off when optimizing side-chain atomic positions.
Structure Superposition
We developed a sequence-dependent structure comparison algorithm (SUP3D) that allows us to automatically optimize a structure alignment based on rigid-body superposition. The algorithm contains three steps: Identify conserved residues from a sequence alignment (seeds); Use the Cα of the seed residues for an initial rigid-body superposition; Iteratively expand the seed fragments with a simple simulated annealing procedure. The algorithm stops when no new residues can be recruited to the superposition list or the rootmean-square deviation threshold is reached. Thus, SUP3D yields a list of superimposed residues with a given RMSD threshold. The length and the number of initial seeds are user-defined with the default values of 3 and 10, respectively. In case the input sequence alignment is inaccurate, a user can define starting seeds for each molecule to be superposed. The simulated annealing procedure is controlled only by a user-defined temperature, 10K by default.
PREDICTION OF THE BINDING MODE OF THE C2 DOMAIN OF THE COAGULATION FACTOR VA WITH PHOSPHOLIPIDIC MEMBRANES Human Coagulation Factor V
The human pro-cofactor V (fV) is a glycoprotein (330 kDa) composed of six domains: A1, B2, B, A3, C1, and C2 ( Fig. 1) . Upon activation by thrombin, the B domain is removed and a heterodimeric active factor V (fVA), comprising of a heavy chain (A1 and A2) and a light chain (A3, C1, and C2), is produced [59] [60] [61] . Inherited fV deficiency, a rare autosomal recessive disease parahemophilia [62] [63] [64] [65] [66] [67] , leads to abnormal bleeding. Hypercoagulability, also known as thrombophilia [68] , may come from mutations in fV such as the factor V Leiden [69] . Hemorrhagic manifestations also result from the presence of inhibitory anti-factor V antibodies [70] . Factor V may play an important role during development of the proteaseactivated G protein-coupled receptors pathway [71] . In addition, fV has an anticoagulant capacity that is dependent on activated protein C-mediated proteolysis of intact fV [72] . Fig. (1) . Organization of the human coagulation factor V domains. Each A domains is made of two plastocyanin-like β-barrels. Each C segment is made up of a discoidin-like β-barrel. Upon activation by thrombin, the B domain is removed producing an activated heterodimer factor V with Cu 2+ and Ca 2+ ions located at the interface.
Membrane binding is a critical step in the explosion of pro-coagulant activities. It is known that negatively charged phospholipids such as phosphatidylserine (PS) are required [73] in particular for the L isomer [74] . The role of membranes is to concenter coagulation cofactors, enzymes and substrates, thereby to enhance the catalytic efficiency three-to five-fold. It has been shown that the C2 domain of fVa (fVC2) was involved in membrane binding [75] possibly with an additional region in the A3 domain [76] . We aimed at understanding how the fVC2 domain binds to a phospholipid membrane in atomic detail.
Project Rationale
The motivation of building the fVC2 model was the need to identify critical residues involved in membrane binding while experimentally determined structures were not available. It should be mentioned that fVC2 is unrelated to the membrane-targeting C2 domains involved in signal transduction or membrane trafficking. Once the important residues are identified, it is possible to determine the binding orientation of fVC2 to the membrane. The binding orientation was a prerequisite to building a complete model of the activated factor V [77] .
Model Building
Details on the construction of fVC2 can be found elsewhere [78] . Briefly, at the beginning of our modeling work, no detectable homology was found between fVC2 and known crystallographic structures. We used a threading approach [79] , a computer method that detects the fitness of a sequence for a given 3D structure, to discover a statistically significant relation between the sequence of fVC2 and the binding domain of the galactose oxidase (GOBD). Coincidentally, a profile-based multiple sequence analysis revealed an evolutionary link between the C domains of coagulation factors V/VIII and the discoidin domain family [80] . It turned out that the D1 domain of the galactose oxidase (GOBD, [81] ) is a distant member of the discoidin domain family [80] . In our modeling work, the sequence identity between fVC2 and GOBD was as low as 18%, a daring challenge to comparative modelers.
Analysis of the fVC2 Model
The fold of fVC2 is a distorted jelly-roll β barrel, divided into one five-stranded and one three-stranded β sheets (Fig. 2A) . The global shape is a cylinder of about 40Å long and 30Å in diameter. A particularity of the fV C1 and C2 domains is the disulfide bond pattern that ties both N-and C-termini together. Consequently, the N-and Ctermini of both fVC1 and fVC2 must be in close proximity. The fVC2 domain is electrically positive with a net charge of +11e. Knowing that fVa binds predominantly to anionic phospholipids, we initially attempted to locate large electropositive patches on the surface of the fVC2 domain (Fig. 3) . However, none of the reasonable sizes was clearly observed [78, 82] . A survey of the literature revealed that proteins sometimes anchor membranes using solvent-exposed hydrophobic residues, for example the vitamin K-dependent coagulation factors [73] and the annexin V [83] . In our model ( Fig. 2A) , we identified four solvent-exposed hydrophobic side chains in the fVC2 domain: Trp2063, Trp 2064, Leu 2116, and Trp 2180 [78] . This region is located on the extremity of the fVC2 cylinder, the opposite side of the N-and C-termini. To view through the virtual plane made of the Cα atoms of these four residues, we found that several positively charged residues adopt a crown-like distribution around the fVC2 cylinder ( Fig. 2A) . Therefore, we proposed a hypothesis that the fVC2 domain anchors to anionic membranes using several solvent-exposed hydrophobic side chains. These side chains interact with the non-polar region of a leaflet; and the entire conformation is further stabilized by the crown-like distribution of positively charged residues which interact with negatively charged phospholipid head groups [78] .
Comparisons Between the Model and the Crystal Structure
One year after the fVC2 model was published, the crystal structures of both coagulation factor V and VIII C2 domains were then determined (Fig. 2B) [84, 85] . A standard measurement of similarity in two structures is evaluating the root-mean-square deviation (RMSD) of Cα atomic coordinates of both molecules. Using our SUP3D program to superimpose the fVC2 model onto the fVC2 crystal structure (the open form, PDB code 1czt), a converged RMSD value of 1.7 Å was reached with 118 residues superimposed. When imposing a threshold RMSD value of 1 Å, SUP3D can only superimpose 72 residues, 45% of the residues in the fVC2 domain, onto the crystal structure. The accuracy of side chain conformation, particularly the χ1 dihedral angle, is a criterion commonly used to evaluate the quality of a model. Our model shares 57% of χ1 dihedral angles with the Xray structure within a range of 40°. The average deviation of χ1 angles of these residues is about 13°. When all modeled residues are included for comparison, Fig. (4) . Sequence alignment based on a structure alignment between the fVC2 comparative model and the Xray crystal structure. Misaligned regions are represented by dashes.
the average deviation rises about 59°. The range of the deviation values is similar to that of our structural predictions in the blind test CASP5 (unpublished data). The finding highlights the remarkable similarity in the two structures of GOBD and fVC2, though their sequence identity is as low as 10%, calculated by the CE program [86] . Inevitably, the fVC2 comparative model carries imperfections, including a major error in the N-terminal region of the model obtained from the sequence-to-sequence alignment (Fig. 4) . This alignment error causes a modeled loop inserted on the top of the fVC2 domain instead of to the bottom. Two additional alignment errors led to a wrong deletion and insertion of two loops; one between strands β4 and β 5, and another between strands β 7 and β 8 (Fig. 4) .
Compared to the comparative model, what new information does the Xray structure of the fVC2 domain bring about? One, it confirmed that the fold of GOBD and fVC2 is identical and that GOBD is a reasonable structural template for modeling fVC2. Two, it confirmed the presence of solvent-exposed hydrophobic side chains, as well as a crown-like distribution of positively charged residues (Fig.  2B) . Three, the Xray diffraction results revealed two forms of fVC2: One denoted as the open form (PDB code 1czs) is characterized by a phenyl-mercury compound covalently bond to Cys2113. The other denoted as the closed form (PDB code 1czv) where Trp2063 and Trp2064 are buried in the shallow pocket that was occupied by the phenyl-mercury compound in the open form. These authors hypothesized that the fVC2 open form corresponds to a circulating conformation while the closed form is a membrane bound conformation [84] . However, no co-crystals between the fVC2 domain and phosphatidyl-L-serine molecules can further support this hypothesis. The exact binding orientation of the fVC2 domain to a membrane remains to be elucidated. Four, the Xray structure confirmed that our prediction about solvent-exposed hydrophobic and positively charged residues are accurate. Table I shows that 8 out of 10 for positively charged residues are confirmed, and 3 out of 4 for hydrophobic side chains are consistent with the Xray structures [87, 88] . Numbers in parenthesis in Table I correspond to the sequential numbering used in the Xray crystal structures. 
Experimental Evidences
Although we are reassured that the Xray structure of fVC2 validates our model, nonetheless the crystal structures provide little novel information on the membrane binding orientation. Once putative functional residues were identified, several laboratories underwent site-directed mutagenesis experiments. The results immediately revealed that a double mutation of the two tryptophan residues 2063 and 2064 impairs the fVa ability to interact with the phospholipids, whereas that of some positively charged residues has little effect [89] . Alternatively, the double mutations of Lys2060-Lys2061 and Trp2063-Trp2064 with Ala showed great reduction in binding to phosphatidyl-Lserine [90] . Fine mapping of inhibitory anti-factor V antibodies revealed that mutations at residues Lys2060, Glu2069, Lys2087, Lys2092, and Glu2096 were significantly resistant to antibody inhibition; the authors suggested these sites involved in phospholipid binding [91] . Taken together, experimental results indicate that solventexposed hydrophobic side chains and positively charged residues are important for membrane binding, which have been previously predicted from our molecular model.
It is known that fV stereospecifically binds to negatively charged phospholipids with a clear preference to phosphatidyl-L-serine instead of phosphatidyl-D-serine [74] . Experiments have found that a single molecule of soluble phosphatidylserine binds to the fVC2 domain with an apparent Kd of 2µM whereas a membrane-associated phosphatidylserine with a value ten times of that [92] . This evidence supports the PLS-binding site as modeled in the fVC2 Xray structure [84] .
Concluding Remarks
We have demonstrated how the derived-knowledge from a theoretical three-dimensional structure leads to prediction of functionally important residues in a molecule. Experimental laboratories immediately took advantage of the knowledge and focussed on these identified residues to validate our hypotheses and predictions.
Despite using a distantly related protein as the structural template, we successfully identified the key residues involved in protein-membrane interactions employing a combinatory approach of structural analysis and bibliographic information mining. Although the precious value of molecular models in advancing biomedical research is without a doubt, it is often unfairly ignored by the community of experimental structure-determination.
We would like to clarify that a successful prediction is not constrained by the so-called "model resolution" but to the extent of the prediction made. In this study case, it would be unreasonable to propose a docking experiment for the fVC2 model and a phosphatidyl-L-serine molecule that is plausible to undertake only when highly accurate coordinates of the Xray structure are available.
Some questions still remain to be answered: whether the residues identified responsible for membrane binding are in direct contact with the specific phospholipid; whether the phosphatidyl-L-serine is pulled-out from the membrane leaflet or the fVC2 domain is inserted into the membrane. We suggest that these questions could be tackled by performing a molecular docking of fVC2 with a phosphadidyl-L-serine in a monolayer of a neutral phospholipid membrane.
STABILIZATION MODE OF POLYNUCLEAR AROMATIC HYDROCARBONS (PAH) BY A MONOCLONAL ANTIBODY PAH's Role in the Environmental Chemistry
Polynuclear aromatic hydrocarbons (PAHs) are fused-ring compounds occurring naturally from man-made combustion products. Individual PAHs vary greatly in their abundance, toxic and carcinogenic potency and environmental impact. Some PAH metabolites form adducts on proteins and DNA that are potential biomarkers of exposure or defective repair. There are about 70 isomeric forms of PAHs with 4 to 6 fused rings. Among them, benzo[a]pyrene (BaP), which consists of five fused rings, is the most studied compound (Fig. 5) . BaP inhibits protein kinase C signal transduction in aortic smooth cells, leading to a deregulation of cell growth, change in DNA repair efficiency, and atherosclerosis [93] . BaP degradation by the P450 complexes [94] leads to diol-epoxide adducts [95] that are recognized as tumorigenic metabolites [96] . BaP is a major source of DNA adducts related to cigarette smoking [97] [98] [99] . A goal of the environmental management projects is the determination of accurate risk based on contaminant characterization. In particular, development of a protocol for determining the human health toxicity of PAHs is required for improving detection of hazardous materials and assessing worker exposure [100] . Several immunoassays [101] [102] [103] and chemiluminescence immunoassays [104] are available to detect the most abundant PAHs. It would be of great value that immunoassays could also distinguish subclasses of PAHs, such as 3,4, or 5-ring compounds, or the major carcinogenic adducts. However, the analogs are so similar that it would be prohibitively difficult and costly to prepare numerous different immunizing and screening haptens and to derive hybridoma antibodies with desired selectivities. We attempted to analyze the PAH-antibody interactions based on the results of molecular modeling and docking that may guide our efforts in the antibody engineering approach. We supposed that rational design cycles of antibodies would provide us the molecules with the desired affinity and selectivity.
Our strategy was based on hybridoma lines 4D5 and 10C10 [105] which were initially derived from mice immunized with BaP hapten conjugated with bovine serum albumin. These two monoclonal antibodies that competitively bind to 3, 4, and 5-ring PAHs have been cloned and expressed. Their affinity, sensitivity, and selectivity were also determined (Bell et al., unpublished) . We used the comparative modeling technique to build models of both antibodies. Docking with various PAHs compounds was then performed and the results were analyzed.
Project Rationale
PAHs are hydrophobic, do not engage in hydrogen binding, and are strictly planar. Immunologic crossreactivity in PAH-antibodies is inevitable. The objective of this work was to define the structural basis and mechanism by which antibodies bind and cross-react with various PAHs. In particular, what energy component is the dominant contribution to stabilization of hapten to and antibody upon binding? Is the recognition mechanism mainly hydrophobic?
Model Building
Comparative models of 4D5 and 10C10 variable fragments (Fvs) were described elsewhere [106] . Fvs are made of a light chain and a heavy chain of about 110 and 120 residues, respectively. Fv binding sites consist of six loops protruding from the conserved β-barrel antibody framework, three from each chain, known as the complementarity determining regions (CDRs). Although Fvs present an additional complexity due to the two chains, there are several hundreds of potential structural templates in the Protein Data Bank [107] . 4D5 and 10C10 Fvs share about 90% sequence identity and we selected the 17/9 crystal structure (PDB code 1HIL, [108] ) as the template to build models of both Fvs. The 17/9 Fv shares about 90% sequence identity in the light chain framework and about 80% sequence identity in the heavy chain either with 4D5 or 10C10. CDRs L1, L2, H1, and H2 were taken from the template antibody whereas CDRL3, with one residue shorter than 4D5 and 10C10, was from the CDRL3 of the HyHEL-5 antibody (PDB code 3HFL, [109] ). CDRH3, which is the most variable CDR in both the sequence and structure, was modeled using the CDRH3 of the TE33 antibody (PDB code 1TET, [110] ). The quality of the model was evaluated by using the PROCHEK package [111] . One important indicator of geometrically reasonable structure is the distribution of φ,ψ dihedral angles [112] . For both 4D5 and 10C10 Fvs, PROCHECK showed 94.4% and 91.3% of the main chain dihedral angles that are located in the most favored regions, respectively, similarly to that of the structural template 1HIL.
Analysis of Antibody Models and PAH Docking
An unusual structural characteristic of the binding sites of 4D5 and 10C10 is the exceptional depth of the pocket, about 17 Å in length, 10 Å in depth, and 7 Å in thickness (Fig. 6 ). It requires: first, a lack of large conserved framework residue (TrpH47) in the heavy chain replaced by Val in 4D5 and Leu in 10C10, respectively; second, the length of the CDRL3 is only eight compared to nine in the classical loop; third, residues with short side chains are needed around the wall of the binding pocket (SerL91, SerH35, GlyH50). Using computer-graphics, a docking of BaP both with 4D5 and 10C10 Fvs was initially performed mainly based on shape complementarity. A structural constraint was imposed on this docking: atom C1 or C8 from which haptens were covalently coupled to protein carriers during immunization or affinity measurements must be accessible to solvent (Fig. 5 ) , thereby limiting the number of orientations of BaP in the Fv binding pocket. A more rigorous docking experiment was then performed using the automated docking program AUTODOCK which adopts a simulated annealing technique for conformation searching with a rapid grid-based energy evaluation method [113, 114] . Several PAHs were docked in both Fvs, including phenanthrene, pyrene, BaP, and BaP-linker.
The results showed a surprising finding that the two BaP-linker haptens, one attached at atom C1 and another at atom C8, bind equally well to both antibodies, even though the linker is located on the opposite faces of BaP (Fig. 6) . To better understand this binding behavior, we docked the BaP hapten alone. We found that the top four binding orientations from the docking results correspond to the four possible orientations of the assumed C2 pseudo-symmetric axes of BaP. On the contrary, automated docking of BaPlinker showed only two preferential binding orientations with the chemical linker exposed to solvent and pointing to the outside of the binding pocket (Fig. 6) . To further analyze multiple docking orientations of PAH to both 4D5 and 10C10 antibodies, we performed docking experiments with BaP (no linker) and pyrene compounds. The results confirm that the antibody binding pockets allow PAHs binding in multiple orientations with quasi-equivalent strength (Fig. 7) . For instance, the top eight conformations of pyrene bound to 10C10 antibody (Fig. 7A) have a relative binding energy range of about 0.3 kcal/mol whereas the energy range for the top four conformations of BaP bound to 10C10 is about 0.7 kcal/mol (Fig. 7B ).
All these docking experiments improved our understanding in the putative binding mode of PAHs in the antibody binding site. It allowed us to identify two unusual residues of the binding pocket that might play a critical role in binding. One, ArgH95, was on the flank of the heavy chain that stacks against one face of PAHs. The other, LysL89, was buried at the bottom of the binding pocket. The two residues usually positively charged present in the binding pocket was puzzling by knowing that the PAH's are highly hydrophobic. It prompted us to calculate the electrostatic property of PAHs. We found that they exerted weak negative electrostatic potentials above and below the aromatic ring plane [115, 106] . The electrostatic potentials were enhanced by the presence either of methyl-urea or methyl-succinate linkers [106] . Hence, we hypothesized that both ArgH95 and LysL89 are important for stabilizing PAHs in the pocket through the so-called π -cation interaction [115] .
Experimental Evidences
To test our hypothesis, site-directed mutagenesis was performed by replacing ArgH95 with a Gln, a frequently occurring amino acid at this position in antibodies, and LysL89 with Met, a residue with a long electrically neutral side chain. Results showed that the mutant ArgH95Gln totally abolished the binding ability of BaP to the 4D5 antibody [115] . However, LysL89Met changed little in binding affinity. The inconsistent result of LysL89Met with our initial hypothesis drove us to further investigating the role of the LysL89 in the binding of PAHs. Theoretical calculations of pKa for LysL89 revealed that this Lys is probably deprotonated at neutral pH (the calculated pKa equals 4.4 compared to 10.5, the standard pKa value). Replacing an electrically neutral residue by a similar one surely has little effect on the binding, thus is consistent with experiment. We therefore speculated that 4D5 and 10C10 antibodies burying such a deprotonated Lys might possess a catalytic activity like known catalytic antibodies. Nevertheless, the new perspective of 4D5 and 10C10 antibodies needs to be further explored. Docking experiment also explained why 4D5 and 10C10 antibodies bind almost equally well to BaP-hapten with various linker types and positions [116] . Our model suggests that the binding pocket is large enough to accommodate various orientations of different PAHs.
CONCLUDING REMARKS
This work allowed us to conclude that BaP and PAHhapten are stabilized by ArgH95 through a novel π-cation interaction in the 4D5 and 10C10 binding pocket. Although cation-π interactions are commonly found in proteins [117, 118] , to the best of our knowledge, it was the first time that an aromatic ligand is stabilized by a cationic charge of the binding site. Compared to the previous work on the fVC2 domain, this work did not focus on identification of a protein function but on the role of individual residues in stabilizing a binding ligand. Plausibility of such a work relies essentially on the high homology in the antibody family. Extremely high homology makes us confident on the accuracy of a comparative model we made. It allows us to perform additional computational analysis on biophysical properties of the molecules. That would not be plausible for models made from molecules distantly related.
CONCLUSIONS
We have presented two projects that revealed how comparative models could have a successful impact in medicinal and environmental chemistry. The first case involved the construction of atomic coordinates of the blood coagulation factor V C2 (fVC2) domain from a distantly related structural template. The fVC2 model drove us to propose a pertinent mechanism for its binding to a phospholipid membrane involving solvent-exposed hydrophobic side chains and a crown of positively charged residues. The second case involved the construction of atomic coordinates of two antibody variable fragments (Fvs) with a closely related structural template. These models of Fvs were used to elucidate the stabilization mechanism of Polynuclear Aromatic Hydrocarbons environmental contaminants in the binding site of these two monoclonal antibodies by which a novel type of protein-ligand interactions, called the π-cation interaction, was identified. Therefore, a useful model must be associated with functional predictions. One may also ask about what the role of molecular models in multi-disciplinary projects is ? As we have described, a comparative model helps us to propose a relevant hypothesis to be tested experimentally. In turn, the model will gain benefit from the experimental feedback and will be updated accordingly; a new hypothesis will then be pursued. The key to successful usage of a model is to find the appropriate limit at which inevitable inaccuracies in models will hamper functional predictions. Indeed, the more accurate the predictions are made, the less time would be spent on experiments. The most prominent example to illustrate the role of molecular model in molecular biology is a hand-built model: the DNA double helix.
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